Cargando…

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 diabetes patients. Strong preclinical evidence suppor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patti, Angelo Maria, Giglio, Rosaria Vincenza, Allotta, Alberto, Bruno, Andreina, Di Bella, Tommaso, Pantea Stoian, Anca, Ciaccio, Marcello, Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216597/ https://www.ncbi.nlm.nih.gov/pubmed/37239033 http://dx.doi.org/10.3390/biomedicines11051362

Ejemplares similares

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2023)

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2020)

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
por: Vekic, Jelena, et al.
Publicado: (2021)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study
por: Terzo, Simona, et al.
Publicado: (2023)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome
por: Suceveanu, Andra-Iulia, et al.
Publicado: (2020)

Comparison of Predictive Value of Cardiometabolic Indices for Subclinical Atherosclerosis in Chinese Adults
por: Xu, Ying, et al.
Publicado: (2014)

Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
por: Rizvi, Ali A., et al.
Publicado: (2021)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Rizvi, Ali A., et al.
Publicado: (2021)

Management of Statin Intolerance in 2018: Still More Questions Than Answers
por: Toth, Peter P., et al.
Publicado: (2018)

Editorial: Diet-microbe-host interactions in metabolic syndrome
por: Gradisteanu Pircalabioru, Gratiela, et al.
Publicado: (2023)

Metabolic disorders during pregnancy and postpartum cardiometabolic risk
por: Patti, Angelo Maria, et al.
Publicado: (2018)

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
por: Patti, Angelo M., et al.
Publicado: (2020)

Variants of PCSK9 Gene Are Associated with Subclinical Atherosclerosis and Cardiometabolic Parameters in Mexicans. The GEA Project
por: Zamarrón-Licona, Erasmo, et al.
Publicado: (2021)

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021)

Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions
por: Sivani, Bala Mohan, et al.
Publicado: (2022)

Risk Factors for Subclinical Atherosclerosis in Diabetic and Obese Children
por: Faienza, Maria Felicia, et al.
Publicado: (2013)

Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease
por: Agnello, Luisa, et al.
Publicado: (2021)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders
por: Agnello, Luisa, et al.
Publicado: (2022)

Subclinical atherosclerosis in young persons horizontally infected with HIV-1 during infancy
por: Cupsa, Augustin, et al.
Publicado: (2012)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

COVID-19 and Alzheimer’s Disease
por: Ciaccio, Marcello, et al.
Publicado: (2021)

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
por: Vekic, Jelena, et al.
Publicado: (2022)

Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy
por: Mureșan, Adrian Vasile, et al.
Publicado: (2023)

Subclinical atherosclerosis in patients with psoriasis
por: Balta, Ilknur, et al.
Publicado: (2015)

Diabetes and Subclinical Coronary Atherosclerosis
por: Lee, Chang Hoon, et al.
Publicado: (2018)

Predictors of subclinical atherosclerosis in HIV
por: Fernández Soto, Julia, et al.
Publicado: (2023)

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
por: Ardeleanu, Valeriu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s3t9k3kserf3db83esa7obdr8m